NEW YORK, March 30 (Reuters) - Prostate cancer vaccine Provenge has long incited passions unlike any other cancer therapy. Doctors who raised doubts about it received death threats. Health regulators ...
announced today that four abstracts featuring PROVENGE^® (sipuleucel-T) data from ongoing Phase II sequencing studies and the PROCEED registry, and two abstracts highlighting preliminary Phase II data ...
November 18, 2010 — The prostate cancer vaccine sipuleucel-T (Provenge, Dendreon) received a middling vote of confidence for its on-label use and what amounted to a thumbs-down vote for its off-label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results